Emerging drugs for the treatment of chronic obstructive pulmonary disease

Expert Opinion on Emerging Drugs
Samir MalhotraDon D Sin

Abstract

By 2020 chronic obstructive pulmonary disease (COPD) will be the third leading cause of mortality and fifth leading cause of morbidity. Research over the past two decades has shed important insights on the pathobiology of COPD, leading to the development of novel drugs. In the past, symptomatic treatment with bronchodilators was the predominant focus of COPD management. With increased awareness of the importance of airway inflammation in COPD progression, there has been a shift in emphasis to drugs that attack various targets in the inflammatory cascade. These drugs include phosphodiesterase 4 inhibitors, leukotriene modifiers and TNF antagonists, which are poised to enter the COPD market in the very near future. Tyrosine kinase antagonists, inhibitors of NF-kappaB, neutrophil elastase inhibitors, chemokine antagonists, mucolytics and novel antibiotics are being evaluated for possible effectiveness in COPD. Many of these drugs may enter the COPD market within the next decade. This paper reviews the molecular rationale for these emerging drugs and their potential efficacy in COPD.

References

Sep 1, 1979·The Journal of Clinical Investigation·E J CampbellC Kuhn
Jun 1, 1989·Critical Care Medicine·J M DebetsC J van der Linden
Dec 10, 1988·BMJ : British Medical Journal·H ChrystynM D Peake
Nov 1, 1994·American Journal of Respiratory and Critical Care Medicine·M Di FranciaJ Orehek
Sep 1, 1996·American Journal of Respiratory and Critical Care Medicine·R Pérez-PadillaM Selman
Jan 1, 1997·European Journal of Immunology·M A CassatellaP P McDonald
Jun 1, 1997·Nature Medicine·G D Massaro, D Massaro
Aug 1, 1997·American Journal of Respiratory and Critical Care Medicine·J E RepineI Lankhorst
Nov 17, 1998·American Journal of Respiratory and Critical Care Medicine·D E O'DonnellK A Webb
Apr 17, 1999·The Journal of Biological Chemistry·K SuetomiJ Navarro
Aug 3, 1999·American Journal of Respiratory and Critical Care Medicine·M SaettaL M Fabbri
Sep 3, 1999·American Journal of Respiratory and Critical Care Medicine·A T HillR A Stockley
Feb 15, 2000·American Journal of Respiratory and Critical Care Medicine·P D ScanlonUNKNOWN Lung Health Study Research Group
Apr 5, 2000·Seminars in Respiratory Infections·J C Hogg
Apr 14, 2000·Naunyn-Schmiedeberg's Archives of Pharmacology·S A SilbaughW T Jackson
Jul 6, 2000·Immunopharmacology·J C LeeJ L Adams
Jul 27, 2000·Annals of the New York Academy of Sciences·J E HenningfieldS Shiffman
Aug 3, 2000·The New England Journal of Medicine·R Medzhitov, C Janeway
Aug 10, 2000·American Journal of Respiratory and Critical Care Medicine·M IchinoseK Shirato
Sep 16, 2000·American Journal of Respiratory and Critical Care Medicine·P MontuschiP J Barnes
Feb 15, 2001·JAMA : the Journal of the American Medical Association·C M MichaudB R Bloom
Feb 24, 2001·American Journal of Respiratory and Critical Care Medicine·G BolteJ Heinrich
Jul 21, 2001·American Journal of Respiratory and Critical Care Medicine·W D BennettJ Johnson
Aug 8, 2001·The European Respiratory Journal·J MajoM G Cosio
Aug 8, 2001·The European Respiratory Journal·R Wilson
Aug 14, 2001·American Journal of Respiratory and Critical Care Medicine·R E KannerUNKNOWN Lung Health Study Research Group
Nov 20, 2001·Current Opinion in Pharmacology·J A Nadel, P R Burgel
Feb 15, 2002·Current Opinion in Pulmonary Medicine·Andrew J SandfordPeter D Paré
Mar 5, 2002·American Journal of Respiratory and Critical Care Medicine·Jenny T MaoMichael D Roth
Apr 20, 2002·Current Opinion in Allergy and Clinical Immunology·D E Davies
May 16, 2002·Chest·Teresa D Tetley
May 16, 2002·Chest·Manuel G CosioMonica G Cosio
May 16, 2002·Chest·Stephen Kilfeather
May 23, 2002·American Journal of Respiratory and Critical Care Medicine·Marina SaettaLeonardo M Fabbri

❮ Previous
Next ❯

Citations

Dec 2, 2010·Nature Reviews. Drug Discovery·Friedrich GrimmingerHossein A Ghofrani
Jan 18, 2011·Expert Opinion on Therapeutic Patents·William C GroutasKevin R Alliston
May 1, 2008·Expert Review of Clinical Immunology·Tammy Sy MuiDon D Sin
Nov 28, 2006·Expert Opinion on Drug Metabolism & Toxicology·John Cl Erve
Jul 17, 2012·The Medical Clinics of North America·Anthony Tam, Don D Sin
Aug 24, 2010·Bioorganic & Medicinal Chemistry·Dengfeng DouWilliam C Groutas
Jan 7, 2009·Therapeutic Advances in Respiratory Disease·Don D SinS F Paul Man
Oct 13, 2015·Acta Crystallographica. Section F, Structural Biology Communications·Stefan HofbauerMargarida Archer
Nov 13, 2009·Journal of Medicinal Chemistry·Jalmira MulchandeRui Moreira
Feb 23, 2008·Journal of Medicinal Chemistry·Jalmira MulchandeJim Iley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.